Gurnet Point recruits Moore as partner

Gurnet Point Capital has appointed David Moore as a partner.

Gurnet Point Capital has appointed David Moore as a partner. Previously, Moore worked at Roivant Sciences where he was CEO of one of its infection diseases businesses.


CAMBRIDGE, Mass.–(BUSINESS WIRE)–Gurnet Point Capital (“Gurnet Point”), a private investment firm focused on health care, announced today that David Moore has been appointed as a Partner of the firm. Mr. Moore, who brings a proven track record of success with both large pharmaceutical and small biotech companies, joins Gurnet Point from Roivant Sciences, a biopharmaceutical drug development company, where he served as Chief Executive Officer of one of its infectious diseases businesses. He also had executive oversight and governance responsibilities for multiple portfolio companies at Roivant, including seeking new investment opportunities.

Prior to his role at Roivant, Mr. Moore was Senior Vice President, Commercial, at Novo Nordisk US, where he led the successful transformation of the company’s commercial operating model into a purely integrated sales and marketing organization. He led the company through multiple new product launches, including one of the most successful launches in Type 2 Diabetes to-date. He also sat on Novo Nordisk’s Global Management Board, the Portfolio Commercialization Board and the Development Steering Committee.

Commenting on Mr. Moore’s appointment, Gurnet Point Capital’s Managing Partner, Chris Viehbacher, said: “We are delighted to have Dave join our Gurnet Point Capital team. He brings with him a strong record of accomplishment as well as deep knowledge of both big pharma and small biotech. Gurnet Point Capital seeks to use the extensive industry experience and network of its team to support the next generation of entrepreneurial leaders as they develop and scale their businesses. Dave will be not only a great addition to our team but also be an invaluable coach, mentor and investor for our current and future portfolio companies. We are excited to be able to work alongside him.”

Mr. Moore said: “I am eager to get started at Gurnet Point Capital and to join a team that has built a genuinely exciting and innovative portfolio of biotech and healthcare companies. I look forward to contributing towards the firm’s exciting future as it enters the next phase of its growth, both in helping to identify and then develop new opportunities for investment.”

Mr. Moore began his career at Ortho-McNeil, a Johnson & Johnson Company business, as a sales representative, progressing through key commercial management roles, including market access, sales leadership, marketing and new product development in a wide variety of therapeutic areas. He later was named Group Marketing Director at Janssen Pharmaceuticals, another Johnson & Johnson business, before making the transition to biotech and taking the position of VP Global Commercial Operations and later Chief Business Officer at Tranzyme Pharma, where, among other responsibilities, he drove the pre-launch of the company’s primary asset. In 2013, Dave was named Chief Commercial Officer (and latterly also President) at biotech company, Cempra Pharmaceuticals, where he transformed the organization from development stage to commercial ready.

About Gurnet Point Capital
Gurnet Point Capital (GPC) is a unique health care fund founded by Ernesto Bertarelli and led by Christopher A. Viehbacher, who, together, have decades of expertise in an industry for which they share a passion, both as Chief Executives and as investors. With an initial allocation of $2 billion, GPC is investing long-term capital and supporting entrepreneurs in building a new generation of companies. Based in Cambridge, MA, its remit is global, encompassing life sciences and medical technologies. The fund invests across all stages of product development through to commercialisation and does so with an approach that is a hybrid of venture and private equity investing strategies. This approach is governed by a guiding tenet that even the earliest of technologies must present a clear commercial case, benefiting both patients and the healthcare system as a whole.